CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 645 enrolled
Drug / intervention
Proxalutamide +1 moredrug
Likely dose
Proxalutamide 300mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04728802
NCT04728802Phase 3Completed
CompareCT.gov

Proxalutamide Treatment for Hospitalized COVID-19 Patients

Applied Biology, Inc.·interventional·Posted Jan 28, 2021·Updated Jun 24, 2021

In Brief

A Phase 3 clinical trial evaluating Proxalutamide and Placebo for Covid19 and SARS (Severe Acute Respiratory Syndrome). Completed, enrolled 645 participants across 8 sites.

Detailed Summary

The purpose of this study is to assess the efficacy and safety of Proxalutamide as a treatment for hospitalized COVID-19 male and female patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19, SARS (Severe Acute Respiratory Syndrome)
CountriesBrazil
Collaborators--

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedJan 28, 2021
Enrollment StartFeb 1, 2021
Primary CompletionApr 15, 2021
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 5.4 years ago

Interventions

Proxalutamidedrug

Proxalutamide 300mg q.d

Placebodrug

Placebo pill